RAC media coverage, page-1194

We were expecting an announcement on the ethics submission for the Cardioprotection trial today according to the AGM. I wonder if this will be tomorrow and therefore be a key focus in tomorrow's investor presentation at the MST event.

I'm surprised the 'Breakthrough Designation' status this caridioprotection trial could attain hasn't attracted more commentary/attention since it was mentioned. The attractiveness to BP being able to expedite the approval process using P2 data, negating the need to run a large, expensive P3 trial would be incredibly attractive in an indication that there is ZERO competition! Add to that, the new IV formulation has extended the IP protection into the 2040s and I can imagine there will be quite a few pharma companies who would be very interested in partnering with RACE on this trial.

As Phil said, they will finally have some tangible market data to put a value on the size of the cardioprotection opportunity to attract institutional interest. But for me, it is the pharma partners they choose to collaborate with that will provide the SP inflection points. Not too far away now IMO.